Coya Therapeutics vs Palatin Technologies
Palatin Technologies reported revenue of $9 million in fiscal 2026, about the same as Coya Therapeutics' $8 million in fiscal 2025. Coya Therapeutics had an operating margin of -283.9%, against -98.2% at Palatin Technologies. Their fiscal years end in different months (December 31 and June 30), so the periods don't line up exactly.
Side by side
| Coya Therapeutics | Palatin Technologies | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Jun 30, 2026 |
| Revenue | $8M | $9M |
| Revenue growth | 123.6% | — |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −283.9% | −98.2% |
| Net margin | −267.1% | −94.9% |
| Free cash flow | — | −$14M |
| Free cash flow margin | — | −153.8% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 9.8% | 425.2% |
| Last close | $2.98 | $4.93 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $9,458 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Coya TherapeuticsPalatin Technologies
Operating margin
Percent of revenue
Coya TherapeuticsPalatin Technologies
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Coya TherapeuticsPalatin Technologies
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Coya Therapeutics and Palatin Technologies pages.